Talk about burying bad news.

At an industry conference last summer, Collegium Pharmaceuticals (COLL) prominently touted the benefits of its Xtampza ER opioid painkiller with a striking display panel at its exhibit booth. The promotional tool sported a well-designed illustration in different colors and font sizes that conveyed an upbeat message for those attending the gathering of the American Society of Health-System Pharmacists in Minneapolis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ed, it’s Xtampza ER, not Xtamza ER. “tamp”, as in hard to tamper with. the blurb in today’s Stat+ email also contains this typo.
    It is harder to tamper with than OxyContin, but I guarantee that’s not why some insurers are covering it instead of OxyContin — it’s all about cost despite their attempt to turn it into positive PR.

    • Thanks, TW. Looks like the ‘p’ was dropped a couple of times. Thanks for noting that.
      And I agree with you that the cost is the issue. Collegium touted one of the first deals as value based, although details were skimpy.
      regards
      ed at pharmalot

  • And so OPDP is ‘on the board’ for 2018 with 1 letter posted. Will it exceed last year’s total of 5 letters posted (although we didn’t see the fifth until we were weeks into 2018.)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy